“we will shortly see a readout over a head-to-head study with Entyvio.”

In context

“d avoidance of demonstration projects? And how important is avoidance of demonstration projects? Thank you. Jeffrey Stewart: Yeah. Hi, Steve. It's Jeff. Just maybe a few comments. You know, I've outlined how stable our capture rates are. Look, it is a competitive market. There have been changes in terms of frontline and later lines, but we're very, very confident that we're going to see very significant growth in leadership with SKYRIZI over IBD as well as the RINVOQ dynamic we discussed. Now what are some things that we can think about and are thinking about in terms of continuing the momentum and even increasing our momentum? First, you know, if this is not a zero-sum game with the two IL-23s. There's a lot of other products in the marketplace. And I think that we've highlighted before, we will shortly see a readout over a head-to-head study with Entyvio. Entyvio is the leading agent or close to it with SKYRIZI in UC, and it does pretty well in Crohn's as well. So with the head-to-head data for SKYRIZI versus Entyvio, we see a significant opportunity to continue the momentum beyond just the IL-23 growth and the competition that we've been talking about. The other dynamic that we see there is a modest, I would say, market value driver. It gets a lot of play over this idea of a sub-q induction versus an IV induction. And as Roopal highlighted in his prepared remarks, we will close that gap. We believe, sometime in early twenty-seven. Based on the readout that we're anticipating. So we have, you know, many, many strategies that we continue to pursue to make sure that we can maintain and sustain our SKYRIZI leadership over time. Robert Michael”